Cochrane · systematic review · CD010432
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
Li, X, Xu, S, Tan, Y, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
18
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 10 · 35.7%Very low 1 · 3.6%Low 6 · 21.4%Moderate 9 · 32.1%High 2 · 7.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with newly diagnosed AML
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at 2 years | HR 0.9 [0.84, 0.96] | 12 studies · 5976 participants | High |
Mortality/relapse at 2 years | HR 0.88 [0.81, 0.96] | 8 studies · 3070 participants | Moderate Downgraded: risk of bias |
Complete remission | RR 1.04 [1.01, 1.07] | 18 studies · 6692 participants | Moderate Downgraded: risk of bias |
Death on induction therapy | RR 1.18 [1.01, 1.36] | 14 studies · 6349 participants | Moderate Downgraded: risk of bias |
Relapse | RR 0.88 [0.8, 0.98] | 4 studies · 1091 participants | Moderate Downgraded: risk of bias |
Grade 3/4 cardiotoxicity | RR 0.98 [0.7, 1.37] | 6 studies · 2795 participants | Moderate Downgraded: risk of bias |
Quality of life not reported | no estimate extracted | 0 participants | Ungraded |
Comparison
Population: patients with newly diagnosed AML
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at 2 years | HR 0.98 [0.89, 1.08] | 6 studies · 2171 participants | High |
Mortality/relapse at 2 years | HR 0.88 [0.7, 1.1] | 4 studies · 249 participants | Low Downgraded: risk of bias, imprecision |
Complete remission | RR 0.97 [0.92, 1.03] | 8 studies · 2411 participants | Moderate Downgraded: risk of bias, imprecision |
Death on induction therapy | RR 1.1 [0.88, 1.38] | 5 studies · 2055 participants | Moderate Downgraded: risk of bias, imprecision |
Relapse | RR 0.99 [0.8, 1.22] | 3 studies · 328 participants | Moderate Downgraded: risk of bias, imprecision |
Grade 3/4 cardiotoxicity | RR 0.67 [0.11, 3.88] | 1 study · 160 participants | Low Downgraded: risk of bias, imprecision |
Quality of life not reported | no estimate extracted | 0 participants | Ungraded |
Comparison
Population: patients with newly diagnosed AML
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at 2 years not reported | no estimate extracted | 0 participants | Ungraded |
Mortality/relapse at 2 years | HR 0.62 [0.34, 1.14] | 1 study · 63 participants | Low Downgraded: risk of bias |
Complete remission | RR 1.28 [1.03, 1.59] | 2 studies · 187 participants | Low Downgraded: risk of bias |
Death on induction therapy not reported | no estimate extracted | 0 participants | Ungraded |
Relapse not reported | no estimate extracted | 0 participants | Ungraded |
Grade 3/4 cardiotoxicity | RR 0.31 [0.01, 7.39] | 1 study · 100 participants | Very low Downgraded: risk of bias |
Quality of life not reported | no estimate extracted | 0 participants | Ungraded |
Comparison
Population: patients with newly diagnosed AML
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at 2 years not reported | no estimate extracted | 0 participants | Ungraded |
Mortality/relapse at 2 years | HR 1.25 [0.83, 1.88] | 1 study · 155 participants | Low Downgraded: risk of bias |
Complete remission | RR 1.04 [0.96, 1.13] | 2 studies · 964 participants | Low Downgraded: risk of bias |
Death on induction therapy | RR 0.75 [0.5, 1.13] | 2 studies · 964 participants | Moderate Downgraded: risk of bias |
Relapse not reported | no estimate extracted | 0 participants | Ungraded |
Grade 3/4 cardiotoxicity not reported | no estimate extracted | 0 participants | Ungraded |
Quality of life not reported | no estimate extracted | 0 participants | Ungraded |